伊利诺伊州班诺克本，2018 年 5 月 16 日 — Survival may improve when advanced heart failure patients receiving home infusion of inotropic therapy are also receiving guideline-directed care, suggest results of a large study recently published in The Journal of Heart and Lung Transplantation.[*]Havakuk O, Tran J, Artig-Brown T, et al. Intravenous inotropes, beta blockers and survival in ambulatory heart failure patients — a contemporary study in 3,311 patients. J Heart Lung Transplant. 2018;37(4)(suppl):S202.  The study was conducted by investigators from Keck School of Medicine of USC and Option Care Health, the nation’s largest independent provider of home and alternate treatment site infusion services.

Patients with advanced heart failure (Stage D) may be prescribed intravenous (IV) inotropic therapy while they await a heart transplant or mechanical circulatory support, or as a palliative measure. The therapy may improve quality of life[*]Walther K, Artig-Brown T, et al. The impact of home infusion on quality of life in patients with heart failure receiving home inotropic therapy based on the Minnesota Living With Heart Failure Questionnaire. Poster presented at the 2017 National Home Infusion Association (NHIA) Annual Conference & Exposition: May 22-25, 2017; Orlando, Fla. by enabling patients’ hearts to pump more efficiently, which may increase their energy levels and may help them breathe easier. While previous research found that patients receiving inotropic therapy survived an average of three to six months, the study of Option Care data suggests an average survival of more than two years.[*]Hauptman PJ, Mikolajczak P, George A, Mohr et al. Chronic inotropic therapy in end-stage heart failure. Am Heart J. 2006;152:1096 e1-8. [*]Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory end-stage heart failure. J Card Fail. 2003;9:180-7. Additionally, survival is improved when doctors follow American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guideline recommendations for delivering the therapy, which includes prescribing other medications such as beta blockers.

“Advanced heart failure patients suffer from extreme fatigue and poor quality of life.  Inotropic therapy can make a big difference in their lives, helping them get back to the day-to-day activities that many of us take for granted, such as enjoying time with family,” said Luanda P. Grazette, MD, MPH, principal investigator of the study and associate professor of clinical medicine at the Keck School of Medicine of USC. “As doctors, we sometimes avoid inotropic therapy out of concerns about decreasing survival. Through this research we found that survival on inotropes has improved quite a bit compared to what was observed from studies in the late 1990s and early 2000s. In this study it was not unusual for many patients to live for years on this therapy. This was quite a surprise.”

“Receiving this life-changing therapy in the comfort of home helps patients more fully enjoy their lives,” said Tess Artig-Brown, BSN, MN, co-author of the study and director of Option Care’s Heart Failure Program. “Patients are able to spend more time at home surrounded by family rather than in a hospital or long-term care center where they may be exposed to antibiotic-resistant infections. Home infusion is also much more cost effective than care provided in the hospital or long-term care centers and research has shown that with education and support, these patients are less likely to be readmitted to the hospital.”[*]Meaux N. and Tatiel M. Hospital admission reductions among Stage D heart failure patients participating in a home inotropic infusion program. Poster presented at 7^th Annual Meeting of the American Association of Heart Failure Nurses (AAHFN): June 23-25, 2011; Seattle. 

该研究于最近在法国尼斯举办的国际心肺移植协会第 38 届年会暨科学会议上展示，是迄今为止重点研究长期使用正性肌力药物治疗的一项最大研究。

此项研究包括了 3296 名于 2009 年 5 月至 2016 年 6 月间接受正性肌力药物治疗的晚期心力衰竭患者。接受持续性正性肌力药物治疗的整体生存调整中位数为 771 天。接受正性肌力药物治疗的平均时间为 171.2 天，最少 1 天，最多 2,204 天。大多数患者 2,300 人 (69.8%) 接受了米立农治疗，942 人 (28.6%) 接受了多巴酚丁胺治疗，54 人 (1.6%) 接受了多巴胺治疗。799 名患者 (24.2%) 采用了 β-受体阻滞剂疗法，死亡率降低了 50%。

Earlier studies reported a higher mortality rate among patients on inotropic therapy, but they were conducted when the treatment practices were different, including bolusing (providing a large initial dose) — which has since been determined to be too taxing for the heart — followed by continuous infusion at much higher doses than what is currently used. Most physicians now start patients on the lowest dose and increase it slowly to achieve the desired result. The guidelines note it’s important that prior to advancing to Stage D, heart failure patients are prescribed oral and mechanical therapies as appropriate, such as beta blockers, angiotensin-converting enzyme (ACE) inhibitors or implantable cardioverter defibrillators (ICDs).

关于 Option Care

Option Care Enterprises, Inc. (Option Care) is the nation’s largest and most trusted provider of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCareHealth.com.

结果表明，患者整体受益显著
在 NHIA 会议上展示

BANNOCKBURN, Ill., July 12, 2017 — Advanced heart failure patients who receive home infusion of inotropic therapy benefit from improved quality of life, according to Option Care research presented at the 2017 National Home Infusion Association (NHIA) Annual Conference & Exposition.

Patients with advanced heart failure are prescribed intravenous (IV) inotropic therapy to help their hearts pump more efficiently while they await a heart transplant or mechanical circulatory support (MCS) or to help them spend their remaining days in greater comfort. Studies have shown inotropic therapy provided in the hospital or healthcare facility is effective, but there’s been limited research on home infusion of the treatment.

“Our study shows home inotropic therapy improved quality of life in advanced heart failure patients,”[*]Walther K, Artig-Brown T, et al. The impact of home infusion on quality of life in patients with heart failure receiving home inotropic therapy based on the Minnesota Living With Heart Failure Questionnaire. Poster presented at the 2017 National Home Infusion Association (NHIA) Annual Conference & Exposition: May 22-25, 2017; Orlando. said Kyle Walther, PharmD, lead author of the study and Option Care pharmacy resident. “Because inotropic therapy typically is provided long-term, it’s invaluable that patients have the opportunity to receive this vital care in the comfort of their own homes, so they can continue to spend time with their families and enjoy the best quality of life.”

此项研究包括了 88 名成人心力衰竭患者，他们在开始接受正性肌力药物输液之前以及家庭输液治疗三个月后填写了“明尼苏达州心力衰竭问卷调查” (MLHFQ)。[*]Walther K, Artig-Brown T 等人著作。家庭输液对接受家庭正性肌力药物治疗的心力衰竭患者的影响（基于明尼苏达州心力衰竭问卷调查）。发表于 2017 年美国国家家庭输液协会 (NHIA) 年会与会展；2017 年 5 月 22-25 日；奥兰多市。MLHFQ 通过询问患者 21 个问题来衡量心力衰竭对生活质量的影响，问题范围从呼吸急促到医疗费用不等。较低的分数表示心力衰竭对患者生活质量的影响较小。研究人员将治疗开始时的 MLHFQ 结果与治疗三个月后的结果进行了比较，发现总体而言，所有患者的得分提高了 8.65％，具有统计学意义。MLHFQ 分数显示，正性肌力药物家庭输液治疗在减少呼吸急促（改善 17.13%）、住院时间（改善 17.65%）和医疗费用（改善 20.78%）方面尤其有益。

Patients in the study received one of three types of inotropic medications: milrinone, dobutamine or dopamine. The medication was infused continuously 24 hours a day through an IV inserted in the chest or arm and stored in a small bag or fanny pack, allowing patients to be mobile. The medication was delivered to the home, and a home infusion nurse visited weekly to check the patient’s vitals, blood and infusion site and ensure the equipment was working effectively. Patients had 24/7 telephone access to pharmacists and nurses if they had questions or concerns. This high-touch care allows patients to receive help quickly, without having to wait for a response from their primary care provider or make a trip to the emergency room.

Home infusion is safe, effective and often less costly than inpatient care. For example, high-touch home infusion of inotropic medication featuring consistent clinical monitoring and support significantly reduces hospital admission rates, saving more than $17,000 per patient per year, according to Option Care research.[*]Meaux N. and Tatiel M. Hospital admission reductions among Stage D heart failure patients participating in a home inotropic infusion program. Poster presented at 7th Annual Meeting of the American Association of Heart Failure Nurses (AAHFN): June 23-25, 2011; Seattle. However, an unintended consequence of the 21st Century Cures Act, passed by the U.S. Congress and signed into law in December 2016, is the creation of a gap in Medicare coverage for home infusion of inotropic therapy, effectively taking away funding for patient access to high quality home infusion.

“Medicare pays for the care involved in providing infusion of inotropic therapy, but only if it’s provided in a hospital, nursing home or other health facility,” said Tess Artig-Brown BSN, MN, co-author of the poster and director of Option Care’s Heart Failure Program. “Few patients would choose to be in a facility receiving their care when they can be in their own homes, and our research suggests home infusion of inotropic therapy allows them to do that. Hopefully this will help draw attention to the benefits of improving patient access to high-quality home infusion.”

关于 Option Care
Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.

Media Contact Information:
Lauren Kotarski
312-558-1770
LKotarski@pcipr.com
# # #